Loading
A phase 1/2 trial of Zipalertinib in non-small-cell lung cancer and small-cell lung cancer, run by Cullinan Therapeutics Inc., active and no longer recruiting.
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT04036682 by Cullinan Therapeutics Inc., with 284 participants planned, started 2019-10-31 and due to reach its primary completion in 2025-10-13. Interventions recorded: CLN-081. Conditions listed: Non Small Cell Lung Cancer, EGFR Exon 20 Mutation. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Zipalertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Zipalertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Zipalertinib, EGFR-mutated non-small-cell lung cancer.
Shares Zipalertinib, EGFR-mutated non-small-cell lung cancer.
Shares Zipalertinib, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/